Emergent BioSolutions Inc (EBS)
9.63
+0.23
(+2.45%)
USD |
NYSE |
Nov 22, 10:43
Emergent BioSolutions Revenue (Quarterly): 283.80M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 283.80M |
| June 30, 2024 | 248.10M |
| March 31, 2024 | 292.40M |
| December 31, 2023 | 269.90M |
| September 30, 2023 | 264.00M |
| June 30, 2023 | 331.30M |
| March 31, 2023 | 157.80M |
| December 31, 2022 | 323.10M |
| September 30, 2022 | 222.50M |
| June 30, 2022 | 235.40M |
| March 31, 2022 | 297.90M |
| December 31, 2021 | 633.50M |
| September 30, 2021 | 312.10M |
| June 30, 2021 | 372.10M |
| March 31, 2021 | 321.70M |
| December 31, 2020 | 561.90M |
| September 30, 2020 | 359.30M |
| June 30, 2020 | 371.10M |
| March 31, 2020 | 169.90M |
| December 31, 2019 | 336.20M |
| September 30, 2019 | 276.20M |
| June 30, 2019 | 202.20M |
| March 31, 2019 | 168.90M |
| December 31, 2018 | 244.30M |
| September 30, 2018 | 155.40M |
| Date | Value |
|---|---|
| June 30, 2018 | 203.70M |
| March 31, 2018 | 101.90M |
| December 31, 2017 | 177.82M |
| September 30, 2017 | 133.21M |
| June 30, 2017 | 79.77M |
| March 31, 2017 | 99.60M |
| December 31, 2016 | 104.16M |
| September 30, 2016 | 111.41M |
| June 30, 2016 | 58.49M |
| March 31, 2016 | 71.34M |
| December 31, 2015 | 134.93M |
| September 30, 2015 | 128.85M |
| June 30, 2015 | 90.88M |
| March 31, 2015 | 30.53M |
| December 31, 2014 | 92.95M |
| September 30, 2014 | 93.89M |
| June 30, 2014 | 87.46M |
| March 31, 2014 | 38.49M |
| December 31, 2013 | 85.67M |
| September 30, 2013 | 76.30M |
| June 30, 2013 | 65.60M |
| March 31, 2013 | 30.36M |
| December 31, 2012 | 74.35M |
| September 30, 2012 | 54.01M |
| June 30, 2012 | 53.16M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
157.80M
Minimum
Mar 2023
633.50M
Maximum
Dec 2021
318.20M
Average
305.00M
Median
Revenue (Quarterly) Benchmarks
| Geovax Labs Inc | 2.790M |
| Tonix Pharmaceuticals Holding Corp | 2.822M |
| Abbott Laboratories | 10.64B |
| Insulet Corp | 543.90M |
| SIGA Technologies Inc | 10.01M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 114.80M |
| Total Expenses (Quarterly) | 219.30M |
| EPS Diluted (Quarterly) | 2.06 |
| Enterprise Value | 1.022B |
| Gross Profit Margin (Quarterly) | 56.80% |
| Profit Margin (Quarterly) | 40.45% |
| Earnings Yield | -42.58% |
| Normalized Earnings Yield | -41.78 |